Brief Summary
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Protocol Interventions
Drug: NRM-823
Advanced Physician Search: Immunotherapy
202509215
Brief Summary
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Protocol Interventions
Drug: AZD6750, Drug: rilvegostomig
202505061
Brief Summary
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Protocol Interventions
Biological: XB628, Drug: Zanzalintinib
202412075
Brief Summary
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Protocol Interventions
Drug: Peluntamig (PT217), Drug: Carboplatin + Etoposide, Drug: Atezolizumab